Ivacaftor for patients with cystic fibrosis

@article{Wainwright2014IvacaftorFP,
  title={Ivacaftor for patients with cystic fibrosis},
  author={Claire Elizabeth Wainwright},
  journal={Expert Review of Respiratory Medicine},
  year={2014},
  volume={8},
  pages={533 - 538}
}
  • C. Wainwright
  • Published 11 September 2014
  • Medicine
  • Expert Review of Respiratory Medicine
Ivacaftor is an oral bioavailable potentiator of the cystic fibrosis transmembrane conductance regulator protein. It is the first therapeutic agent that has been registered for clinical use which targets the basic defect in people with cystic fibrosis who carry a G551D mutation or other rarer specific gating mutations. Clinical trials have shown consistent and impressive clinical benefit that appears to be sustained over time in people with cystic fibrosis who carry a G551D mutation and similar… 
Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation
TLDR
Although this combination therapy is the first treatment to directly target the F508del-CFTR mutation, patients taking this drug displayed only modest improvements in lung function, and options for identifying future therapies that will be most efficacious for all CF patients are considered.
Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
TLDR
Understanding the many sources of variability can help reduce this individual patient variability and ensure consistent patient outcomes under CFTR modulator treatment arising from variability in patient outcomes.
Hallmarks of therapeutic management of the cystic fibrosis functional landscape.
  • M. Amaral, W. Balch
  • Medicine
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
  • 2015
TLDR
It is posited that a deep understanding of each patients PN/SN gained by merging genomic, proteomic, and high-content microscopy technologies in the context of novel network learning algorithms will lead to a paradigm shift in CF clinical management.
Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis
TLDR
The taskforce strongly reccommends that medical leadership in multidisciplinary adult teams should be attributed to a respiratory physician adequately trained in cystic fibrosis management, and suggests the implementation of a core curriculum for trainees in adult respiratory medicine and the selection and accreditation of training centres that deliver postgraduate training to the standards of the HERMES programme.
Hyperpolarized 129Xe for investigation of mild cystic fibrosis lung disease in pediatric patients.
TLDR
Hyperpolarized 129Xe MRI demonstrated ventilation defects in CF patients with normal FEV1 and more effectively discriminated CF from controls than FEV said to be a useful outcome measure to detect mild CF lung disease.
Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18 months following approval in the United States.
TLDR
Age, insurance status, disease severity and use of other therapies differed in those prescribed LUM-IVA in the initial post-approval period, and uptake was less rapid than what was previously observed for ivacaftor, a CFTR modulator approved for a different population.
CFTR Function and Clinical Response to Modulators Parallel Nasal Epithelial Organoid Swelling.
TLDR
An in vitro biomarker derived from patients' cells can be used to predict responses to drugs and is likely to be useful as a pre-clinical tool to aid in development of novel treatments, and as a clinical trial outcome measure for a variety of applications, including gene therapy or editing.
Nasospheroids permit measurements of CFTR-dependent fluid transport.
TLDR
Nasospheroids, a primary cell culture-based model derived from individual CF patients and healthy subjects by a minimally invasive nasal biopsy, is developed and is applicable for detection of small changes in CFTR activity from individual patients in vitro.
Keep them breathing: Cystic fibrosis pathophysiology, diagnosis, and treatment
TLDR
The clinical manifestations, diagnosis, and monitoring of patients with CF as well as guidelines for management and emerging pharmacologic treatments are reviewed.
Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO.
TLDR
For the first time HPLC and LC-MS methods were developed and validated for rapid detection and quantification of IVA and its major metabolites hydroxymethyl-IVA M1 (active) and IVA-carboxylate M6 (inactive); and LUMA in the plasma and sputum of CF patients.
...
1
2
...

References

SHOWING 1-10 OF 33 REFERENCES
Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.
TLDR
Lack of a clinical effect suggests that a CFTR potentiator alone is not an effective therapeutic approach for patients who have CF and are homozygous for F508del-CFTR.
Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease.
TLDR
Ivacaftor was clinically effective in patients with CF who carry the G551D mutation and have severe pulmonary disease and the reductions in treatment requirements were clinically and statistically significant and have not been described in less severe populations.
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
TLDR
In patients who are younger and healthier than those in previously studied populations, ivacaftor demonstrated a significant improvement in pulmonary function, weight, and CFTR activity compared with placebo.
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
TLDR
Ivacaftor was associated with improvements in lung function at 2 weeks that were sustained through 48 weeks and substantial improvements were also observed in the risk of pulmonary exacerbations, patient-reported respiratory symptoms, weight, and concentration of sweat chloride.
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
TLDR
This study showed that VX-770 was associated with within-subject improvements in CFTR and lung function and provides support for further studies of pharmacologic potentiation of CFTR as a means to treat cystic fibrosis.
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
TLDR
In this study, VX-809 had a similar adverse event profile to placebo for 28 days in F508del-CFTR homozygous patients, and demonstrated biological activity with positive impact on CFTR function in the sweat gland.
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
TLDR
In patients with cystic fibrosis who have a premature stop codon in the CFTR gene, oral administration of PTC124 to suppress nonsense mutations reduces the epithelial electrophysiological abnormalities caused by CFTR dysfunction.
The use of ivacaftor in an adult with severe lung disease due to cystic fibrosis (ΔF508/G551D).
  • H. Polenakovik, B. Sanville
  • Medicine
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
  • 2013
TLDR
An adult with cystic fibrosis with severe lung disease with forced expiratory volume (FEV1) in one second 24% predicted who was admitted for a pulmonary exacerbation has significant improvement in lung function with normalization of hypercarbia, oxygen saturation on room air, and increase in FEV1 to 36% predicted.
Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein.
TLDR
The patch-clamp technique was used to investigate the effects of the isoflavone genistein on disease-causing mutations (G551D and ΔF508) of the cystic fibrosis transmembrane conductance regulator (CFTR), and it was suggested thatgenistein activated CFTR mutants that were present in the cell membrane.
Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.
  • X. Xue, V. Mutyam, +13 authors S. Rowe
  • Biology, Medicine
    American journal of respiratory cell and molecular biology
  • 2014
TLDR
NB124 treatment rescued CFTR function in a CF mouse model expressing a human CFTR-G542X transgene; efficacy was superior to gentamicin and exhibited favorable pharmacokinetic properties, suggesting that in vitro results translated to clinical benefit in vivo.
...
1
2
3
4
...